Tug life
I stay fly like a guillemot
Sometimes I don't pay attention to the analyst. Remember when some analyst gave Tesla a $10 price target? I think they are trying to scare people to sell to institutions
The Official CORMEDIX (CRMD)thread (run up to FDA approval has begun )
- Thread starter Tug life
- Start date
Yea, I agree, but some folks do.
Tug life
I stay fly like a guillemot
I'm still holding on to this one. I got to greedy and watched my gains disappear.
But it's up about 60% again after hours on good news that their drug prevents cirrhosis. It can run huge tomorrow when the market opens. Hoping for a 100-200% day. It's still in phase 1 but that is extremely good news and this stock is a low float that moves very fast. So I'll trade it tomorrow but I'll think of adding it to my portfolio long term.
Yahoo is now part of Verizon Media
Why did no one say anything
Tug life
I stay fly like a guillemot
Nobody here seen it until after it was $100+Why did no one say anything
Should also keep an eye on the company buying them NOVN at $1.99 a share.
Swiss drugmaker Novartis AG (NOVN.S) is nearing an agreement to acquire U.S. biotechnology firm The Medicines Co (MDCO.O) for about $7 billion, the Wall Street Journal reported on Saturday.
NOVN on NASDAQ isn't Norvatis.
NOVN on SWX Is Novartis.
The confusion comes from having the same ticker but on different stock exchanges.
Why would Gilead buy Amarin?
The lowdown is that Gilead is attempting to develop a top shelf combination treatment for NASH. By doing so, the biotech would be able to leap frog the first-generation of monotherapies set to hit the market as soon as 2020. And it might even be able to establish a competitive moat against the army of big pharmas and big biotechs racing to bring their own combo NASH treatments to market. Vascepa could be Gilead's ticket to unlocking the wide-open $65 billion NASH market.
Why might Vascepa be the missing ingredient in Gilead's NASH quest? Back in April, Gilead unleashed some promising data for the doublet therapy of cilofexor and firsocostat in NASH patients at the International Liver Congress. The drawback was that some of the patients evaluated in the trial exhibited a severe spike in triglyceride levels -- a known side-effect of firsocostat. Presumably, Gilead decided to add a Vascepa arm to explore the drug's ability to combat this potentially serious side effect.
What's more, Vascepa might also provide an all-important cardioprotective benefit in this at-risk patient population. And this second clinical benefit could be a game-changer for the therapy from a commercial standpoint. There is a well-established link between NASH and cardiovascular disease, after all.
What's the key takeaway? While this clinical trial news might turn out to be a big, fat nothingburger, it may also be the first sign that Gilead is considering an Amarin partnership, or perhaps a full-on buyout. The fact is that Gilead is one of the few biopharmas that could buy Amarin in cash without batting an eye. Moreover, Vascepa's potential dual purpose as an add-on to statin-therapy in patients with cardiovascular disease, and as part of a top-selling NASH cocktail, easily justifies the premium a buyout would entail.
Does Amarin Have a Dark Horse Suitor? | The Motley Fool
Hopefully the bolded means what most of us are thinking. The price tag on AMRN is HUGE.